Back to Peptides
Hormone FDA Approved

Pasireotide

An FDA-approved somatostatin analog marketed as Signifor, used in Cushing's disease and related endocrine settings.

Somatostatin AnalogFDA ApprovedCushing's DiseaseEndocrine

Also referenced as: Signifor, Signifor LAR

Status
FDA Approved

This peptide maps to at least one regulated medical product or label context in the United States.

Category
Hormone

This profile is grouped by its dominant research and market lane, not by vendor shelf placement.

Aliases
2

Signifor, Signifor LAR

Signal depth
High

FDA label signal · 87 trials · 751 PubMed results

What pasireotide is

Pasireotide is an FDA-approved somatostatin analog marketed as Signifor and Signifor LAR.

Why it matters

It gives the library another important approved endocrine peptide and helps distinguish the different drugs within the somatostatin-analog family.

Regulatory context

Pasireotide is FDA approved in the United States for specific endocrine indications.

Practical reading note

Even peptides in the same broad family can differ a lot in real-world indication, receptor profile, and clinical use.